Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

(2008) Nagma Khan et al.   BIOCHEMICAL JOURNAL

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

419 POSTER A phase I safety and pharmacokinetic (PK) study of 3 and 6 hours (h) intravenously administered belinostat (PXD101) plus carboplatin (C) and paclitaxel (P) in patients (pts) with advanced solid tumours

(2008) M. Sorensen et al.   EJC SUPPLEMENTS

420 POSTER A phase I clinical trial of belinostat (PXD101) in combination with doxorubicin (BelDox) in advanced solid tumours, including soft tissue sarcomas (STS)

(2008) A.T. Brunetto et al.   EJC SUPPLEMENTS

213 POSTER Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder

(2008) J. Barriuso et al.   EJC SUPPLEMENTS

404 POSTER A phase I study of oral administration of the histone deacetylase (HDAC) inhibitor belinostat in patients (pts) with advanced solid tumors

(2008) W. Kelly et al.   EJC SUPPLEMENTS

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY